Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 44Squamous Cell Carcinoma of Head and Neck 19Breast Neoplasms 18Lung Neoplasms 17Colorectal Neoplasms 15Neoplasms 12Neoplasm Metastasis 12Head and Neck Neoplasms 12Ovarian Neoplasms 11Small Cell Lung Carcinoma 9Recurrence 9Sarcoma 8Pancreatic Neoplasms 8Prostatic Neoplasms 7Advanced Solid Tumors 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Diabetes Mellitus, Insulin-Dependent, 12 6Uterine Cervical Neoplasms 5Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 5Biliary Tract Neoplasms 5Mesothelioma, Malignant 4Lymphoma, Follicular 4Lymphoma 4Fallopian Tube Neoplasms 4Esophageal Neoplasms 4Cholangiocarcinoma 4

Interventions

tremelimumab 1durvalumab 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Malignancy × durvalumab × Clear all
NCT02978482 2021-08-18

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

AstraZeneca

Phase 1 Completed
26 enrolled

Advanced Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡